Rilpivirine
Rilpivirine is an antiviral medicine (an NNRTI) taken by mouth with other HIV medicines to treat HIV-1 infection, and it can also be used with cabotegravir around monthly or less frequent injection treatment.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 3 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Rilpivirine (Edurant) is an HIV medicine, an NNRTI that blocks an enzyme the virus needs to copy itself, combined with other HIV medicines or briefly paired with cabotegravir around injection treatment; on the market since about 2010 and available generically, it is an established choice for people starting treatment with a lower viral load. Most people tolerate it well, with headache, poor sleep or low mood the most noticed effects. A severe rash (especially with fever, blisters or facial swelling), serious depression or signs of liver trouble need prompt medical attention. Its levels drop easily, so take it with a meal and have every new medicine or supplement checked.
Clinical pearls
- Proton pump inhibitors such as omeprazole and pantoprazole, plus St. John's wort, are completely off-limits, not just a matter of spacing.
- Take antacids at least 2 hours before or 4 hours after rilpivirine, and famotidine 12 hours before or 4 after.
- A protein drink alone does not count as the meal; it needs real food to be absorbed well.
- Edurant Ped and the regular tablet are not swappable milligram for milligram, so confirm the product at each refill.
Patient information guide A plain-language walkthrough of Rilpivirine, written from its FDA label.
What Rilpivirine is used for
▾
Rilpivirine treats HIV-1 infection, always with other HIV medicines.
- Edurant and Edurant Ped: HIV-1 in treatment-naïve patients age 2 and older weighing at least 14 kg, with viral load of 100,000 copies/mL or lower.
- Rilpivirine tablets: HIV-1 in treatment-naïve patients age 12 and older weighing at least 35 kg, with viral load of 100,000 copies/mL or lower.
- Edurant and Rilpivirine tablets: short-term use with Vocabria (cabotegravir) in eligible adults and teens (12 and older, at least 35 kg) whose virus is suppressed.
- That cabotegravir use covers a tolerability trial before Cabenuva injections, or oral backup when planned injections will be missed.
How Rilpivirine works
▾
Rilpivirine is an HIV-specific antiviral in the NNRTI class. It is used together with other HIV medicines to control the virus.
Rilpivirine dosage
▾
The tablets are taken by mouth once daily with a meal, along with your other HIV medicines. Food helps your body absorb the medicine properly.
- Edurant Ped is mixed in drinking water and taken immediately with a meal.
- Edurant tablets and Edurant Ped are not interchangeable.
- With rifabutin, the dose is changed, so follow your prescriber.
- Follow your prescriber and the label for the cabotegravir regimen and for missed doses.
Dosing details from the FDA-approved label
From the Rilpivirine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Treatment-naïve adult patients
- One 25 mg tablet taken orally once daily with a meal
- Pediatric patients 2 years of age and older, weighing 14 kg to less than 20 kg (EDURANT PED)
- 5 tablets (2.5 mg) once daily, 12.5 mg EDURANT PED once daily, dispersed in drinking water and taken with a meal
- EDURANT 25 mg tablets not recommended; EDURANT PED not substitutable milligram-per-milligram for EDURANT tablets
- Pediatric patients 2 years of age and older, weighing 20 kg to less than 25 kg (EDURANT PED)
- 6 tablets (2.5 mg) once daily, 15 mg EDURANT PED once daily, dispersed in drinking water and taken with a meal
- EDURANT 25 mg tablets not recommended
- Pediatric patients weighing greater than or equal to 25 kg (EDURANT)
- 1 tablet (25 mg) once daily with a meal
- EDURANT PED not recommended; the generic rilpivirine label lists 12 years and older and at least 35 kg
- Pregnant patients already on a stable regimen and virologically suppressed (HIV-1 RNA less than 50 copies per mL)
- One 25 mg tablet once daily taken orally with a meal
- Lower exposures observed during pregnancy; monitor viral load closely
- Coadministration with rifabutin
- Two 25 mg tablets of EDURANT once daily with a meal for the duration of the rifabutin coadministration
- Dose is 50 mg once daily; decrease to 25 mg once daily when rifabutin is stopped
- Oral lead-in with cabotegravir (adults and adolescents 12 years and older, weighing at least 35 kg)
- One 25 mg EDURANT tablet with one 30 mg VOCABRIA (cabotegravir) tablet orally once daily at about the same time each day with a meal, for approximately 1 month (at least 28 days)
- Last oral dose taken on the same day CABENUVA injections start
- Oral dosing to replace planned missed monthly CABENUVA injections (missing by more than 7 days)
- One 25 mg EDURANT tablet and one 30 mg VOCABRIA tablet once daily with a meal for up to 2 months
- Beyond 2 months an alternative oral regimen is recommended
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION One 25 mg EDURANT tablet taken once daily with a meal for patients weighing at least 25 kg. ( 2.2 ) Pediatric patients 2 years of age and older and weighing at least 14 kg to less than 25 kg: Dosage of EDURANT PED is based on body weight. ( 2.3 ) EDURANT PED must be dispersed in drinking water and taken with a meal. ( 2.4 ) Do not substitute EDURANT tablets and EDURANT PED tablets for oral suspension on a milligram-per-milligram basis due to differing pharmacokinetic profiles. ( 2.1 , 5.6 ) See full prescribing information for dosing information when used in combination with cabotegravir. ( 2.6 ) For pregnant patients who are already on a stable EDURANT regimen prior to pregnancy and who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) the recommended dosage in adults and pediatric patients weighing more than 25 kg is one 25 mg tablet once daily taken orally with a meal. ( 2.5 , 12.3 ) Rifabutin coadministration: Take two 25 mg tablets of EDURANT once daily with a meal for the duration of the rifabutin coadministration. ( 2.7 ) 2.1 Overview of Different Dosage Forms EDURANT is available in two dosage forms: EDURANT 25 mg film-coated tablets for adults and pediatric patients weighing at least 25 kg. EDURANT PED 2.5 mg tablets for oral suspension should only be given to pediatric patients weighing at least 14 kg to less than 25 kg [see Dosage and Administration (2.3) ] . Do not substitute EDURANT tablets and EDURANT PED tablets for oral suspension on a milligram-per-milligram basis due to differing pharmacokinetic profiles. A difference in bioavailability between 1 × 25 mg film-coated tablet and 10 × 2.5 mg tablets for oral suspension was observed; therefore, they are NOT substitutable [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3) ]. Take EDURANT and EDURANT PED once daily with a meal in combination with other antiretrovirals [see Clinical Pharmacology (12.3) ]. 2.2 Recommended Dosage in Treatment-Naïve Adult Patients The recommended dosage of EDURANT in adult patients is one 25 mg tablet taken orally once daily with a meal [see Use in Specific Populations (8.1) and Clinical Pharmacology (12.3) ] .
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Rilpivirine side effects
▾
The most common side effects of at least moderate intensity were:
Common side effects
- Depressed mood or other depression-related symptoms
- Headache
- Trouble sleeping (insomnia)
- Rash
When to get medical help
- Severe rash, or a rash with fever, blisters, mouth sores, red eyes, or swelling of the face: stop the medicine and get medical help right away
- Signs of liver problems or a drug reaction involving the liver: tell your doctor promptly
- Severe depression, or thoughts of suicide: get medical help right away
- New symptoms of infection or inflammation soon after starting HIV treatment (immune reconstitution syndrome): contact your doctor
- Overdose: call a poison control center
Rilpivirine warnings and precautions
▾
- Severe skin and allergic reactions, including DRESS, can happen; stop and get help if you have severe rash, fever, blisters or facial swelling.
- Liver problems can occur, especially with hepatitis B or C.
- Severe depression and suicidal thoughts have been reported.
- Drug interactions can reduce effectiveness and lead to resistance.
- Immune reconstitution syndrome can occur early in HIV treatment.
Rilpivirine interactions
▾
Many medicines change rilpivirine levels, so tell your pharmacist about everything you take.
- Carbamazepine, oxcarbazepine, phenobarbital, phenytoin: not allowed, lower levels.
- Rifampin, rifapentine: not allowed, lower levels.
- Proton pump inhibitors: not allowed, less stomach acid lowers absorption.
- St. John's wort: not allowed.
- Antacids and H2 blockers: must be spaced apart from rilpivirine.
- Rifabutin: rilpivirine dose is adjusted.
- Other NNRTIs: not recommended.
- Macrolides and other QT-prolonging drugs: alternatives may be considered.
Interactions listed in the FDA-approved label
From the Rilpivirine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Antacids (e.g., aluminum or magnesium hydroxide, calcium carbonate): Concomitant intake may cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). Use with caution; give antacids only at least 2 hours before or at least 4 hours after rilpivirine.
- Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin: Decrease rilpivirine concentrations. Coadministration is contraindicated.
- Rifampin, rifapentine: Decrease rilpivirine concentrations. Coadministration is contraindicated.
- Rifabutin: May decrease rilpivirine plasma concentrations (induction of CYP3A enzymes). Increase rilpivirine from 25 mg once daily to 50 mg once daily during coadministration; decrease to 25 mg once daily when rifabutin is stopped.
- Azole antifungal agents (fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole): May increase rilpivirine plasma concentrations (inhibition of CYP3A enzymes). No rilpivirine dose adjustment required; clinically monitor for breakthrough fungal infections.
- Systemic glucocorticoid: dexamethasone (more than a single-dose treatment): Decreases rilpivirine concentrations. Coadministration is contraindicated.
- H2-receptor antagonists (cimetidine, famotidine, nizatidine, ranitidine): May cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). Use with caution; give only at least 12 hours before or at least 4 hours after rilpivirine.
- St. John's wort (Hypericum perforatum): Decreases rilpivirine concentrations. Coadministration is contraindicated.
- Other NNRTIs (delavirdine, efavirenz, etravirine, nevirapine): Delavirdine increases rilpivirine; other NNRTIs decrease rilpivirine. Coadministration is not recommended.
- Macrolide or ketolide antibiotics (azithromycin, clarithromycin, erythromycin): Expected to increase rilpivirine concentrations and associated with a risk of Torsade de Pointes. Where possible consider alternatives, such as azithromycin, which increases rilpivirine concentrations less than other macrolides.
Read the label’s full interactions text
7 DRUG INTERACTIONS Rilpivirine is primarily metabolized by cytochrome P450 (CYP)3A, and drugs that induce or inhibit CYP3A may thus affect the clearance of rilpivirine. Coadministration of rilpivirine tablets and drugs that induce CYP3A may result in decreased plasma concentrations of rilpivirine and loss of virologic response and possible resistance to rilpivirine or to the class of NNRTIs. Coadministration of rilpivirine tablets and drugs that inhibit CYP3A may result in increased plasma concentrations of rilpivirine. Coadministration of rilpivirine tablets with drugs that increase gastric pH may result in decreased plasma concentrations of rilpivirine and loss of virologic response and possible resistance to rilpivirine or to the class of NNRTIs. Rilpivirine tablets at the recommended doses are not likely to have a clinically relevant effect on the exposure of drugs metabolized by CYP enzymes. Table 6 shows the established and other potentially significant drug interactions based on which alterations in dose or regimen of rilpivirine tablets and/or coadministered drug may be recommended. Drugs that are not recommended for coadministration with rilpivirine tablets are also included in Table 6. [see Dosage and Administration ( 2 ), Contraindications ( 4 ), and Clinical Pharmacology ( 12.3 )]. Table 6: Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction [see Clinical Pharmacology (12.3)] ↑=increase, ↓=decrease, ↔=no change * The interaction between rilpivirine tablets and the drug was evaluated in a clinical study. All other drug-drug interactions shown are predicted. † This interaction study has been performed with a dose higher than the recommended dose for rilpivirine tablets assessing the maximal effect on the coadministered drug. The dosing recommendation is applicable to the recommended doses of rilpivirine once daily.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Rilpivirine
▾
- Tell your doctor about liver disease, hepatitis B or C, or depression.
- Pregnancy: levels are lower, so viral load is monitored closely.
- Breastfeeding: the drug is in breast milk, with risks of HIV transmission or resistance.
- Children need the product matched to their age and weight.
- Older adults: use with caution.
- Severe kidney disease: caution and extra monitoring.
- Severe liver impairment has not been studied.
Rilpivirine overdose
▾
There is no specific antidote for rilpivirine overdose. Treatment is supportive care, including monitoring vital signs and heart rhythm (ECG). Contact a poison control center for current advice.
What Rilpivirine does in the body
▾
At the recommended dose, rilpivirine did not meaningfully change the heart's QT interval in healthy adults. At 3 and 12 times the recommended dose, it did lengthen the QT interval. That is why other QT-prolonging medicines need caution.
How your body processes Rilpivirine
▾
After a dose, blood levels peak in about 4 to 5 hours. Exposure is about 40% lower on an empty stomach than with a meal, and about 50% lower with only a protein drink. Rilpivirine is processed mainly by the CYP3A liver enzyme system, and most is cleared in the stool. Its half-life is about 50 hours.
How to store Rilpivirine
▾
Store EDURANT tablets in the original bottle in order to protect from light. Store EDURANT tablets at 20° to 25°C (68° to 77°F); with excursions permitted to 15° to 30°C (59° to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Rilpivirine
175 supplements and herbal products have documented interactions with Rilpivirine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 11
- Moderate · 127
- Minor · 37
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Rilpivirine: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Rilpivirine — the kind of thing our pharmacy team would talk through with you at the counter.
What is rilpivirine for?
▾
How should I take it?
▾
What side effects should I expect?
▾
When should I call my doctor right away?
▾
Can I take my heartburn medicine with it?
▾
What if I am pregnant or breastfeeding?
▾
Is Rilpivirine available over the counter?
▾
When was Rilpivirine first available?
▾
Who makes Rilpivirine?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Rilpivirine on HelloPharmacist
Rilpivirine forms and strengths (how it comes)
Rilpivirine is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Edurant and Edurant Ped are used with other antiretrovirals for HIV-1 in treatment-naïve patients age 2 and older weighing at least 14 kg.
- Rilpivirine tablets are used with other antiretrovirals for HIV-1 in treatment-naïve patients age 12 and older weighing at least 35 kg.
- Edurant and Rilpivirine tablets are used with Vocabria (cabotegravir) for short-term treatment in eligible virologically suppressed patients.
- Edurant and Rilpivirine tablets are taken once daily by mouth with a meal.
- Edurant Ped is dispersed in drinking water and taken right away with a meal; it is not chewed or swallowed whole.
- Edurant tablets and Edurant Ped are not substitutable milligram for milligram.
Injection
Rilpivirine on the U.S. market: products, makers and brands
How Rilpivirine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
3 companies list 4 Rilpivirine product records with the FDA, mostly as tablet, injection; the earliest marketing or approval year on record is 2010. Brand names on the directory include Edurant, Edurant Ped; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (14) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Rilpivirine is used (Medicaid data)
A general measure of how commonly Rilpivirine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Rilpivirine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Rilpivirine prescribed? Of the 1,601 medications we measure, Rilpivirine ranks #592 by Medicaid prescriptions — more than 63% of them.
Utilization by Rilpivirine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
rilpivirine 25 MG Oral Tablet
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1102273
Other Rilpivirine products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 2 of 27 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Rilpivirine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 3 of 29 listed Rilpivirine NDCs with Medicaid activity.
Compare Rilpivirine products
A representative set of FDA-listed product records for Rilpivirine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 2.5 mg | Oral | Janssen Products, LP | NDA | View NDC → |
| 25 mg | Oral | Janssen Products, LP | NDA | View NDC → |
| 25 mg | Oral | Laurus Labs Limited | ANDA | View NDC → |
| 25 mg | Oral | Somerset Therapeutics, LLC | ANDA | View NDC → |
Showing 4 of 4 products — FDA National Drug Code Directory. See every product, package size and price: browse all 4 Rilpivirine NDCs →
Rilpivirine side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Rilpivirine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Rilpivirine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Rilpivirine FDA approval history
How Rilpivirine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Rilpivirine recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Rilpivirine recalls since July 2021.
✅No Rilpivirine recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1102270 3 dose forms · 4 strengths
-
Dose form (SCDF) Injection RxCUI 2594979In current FDA listingsClinical drug / strength (SCD) 2 ML rilpivirine 300 MG/MLRxCUI 25949823 ML rilpivirine 300 MG/MLRxCUI 2594980 -
Dose form (SCDF) Oral Tablet RxCUI 1102272In current FDA listingsClinical drug / strength (SCD) 25 MGRxCUI 1102273 -
Dose form (SCDF) Tablet for Oral Suspension RxCUI 2678243In current FDA listingsClinical drug / strength (SCD) 2.5 MGRxCUI 2678244
Look up RxCUI 1102270 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Rilpivirine supply and shortage status
Whether Rilpivirine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Rilpivirine brand names
Rilpivirine is sold under 2 brand names in the FDA directory — Edurant, Edurant Ped. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Rilpivirine: manufacturers and labelers
3 companies list Rilpivirine products with the FDA. By number of product records, the largest are Janssen Products, LP, Laurus Labs Limited, Somerset Therapeutics, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Rilpivirine drug class (RxNorm)
Rilpivirine belongs to the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Rilpivirine page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Somerset Therapeutics, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →